Evidence map›Paper›PMID 41774544›Full record

ArticleSTAR protocols2026

Protocol for establishing a chemoresistant orthotopic triple-negative breast cancer patient-derived xenograft model for preclinical drug testing.

David Tébar-García, Rosa Barbella-Aponte, Esther Sánchez-López, Maria G Picazo-Martínez, Mónica Gómez-Juárez, Ángela Díaz-Piqueras, Alejandro Pinedo-Serrano, Paula Sánchez-Olivares, Raquel López-Rosa, Pablo Cristobal-Cueto and 2 more

Abstract read
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David Tébar-GarcíaCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain. Electronic address: david.tebar@uclm.es.
Rosa Barbella-AponteAnatomic Pathology Service, Albacete University Hospital, Albacete, Spain.
Esther Sánchez-LópezSurgical Unit, Albacete University Hospital, Albacete, Spain.
Maria G Picazo-MartínezExperimental Research Unit of General University Hospital of Albacete, Spain Albacete, Spain.
Mónica Gómez-JuárezExperimental Research Unit of General University Hospital of Albacete, Spain Albacete, Spain.
Ángela Díaz-PiquerasExperimental Research Unit of General University Hospital of Albacete, Spain Albacete, Spain; Biobank, Albacete University Hospital, Albacete, Spain.
Alejandro Pinedo-SerranoCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain.
Paula Sánchez-OlivaresCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain.
Raquel López-RosaCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain.
Pablo Cristobal-CuetoCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain.
Verónica RodillaCancer Heterogeneity and Hierarchies Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain.
Eva M Galán-MoyaCancer Pathophysiology and Therapy Lab Institute of Biomedicine of the University of Castilla-La Mancha (IB-UCLM), Albacete, Spain. Electronic address: evamaria.galan@uclm.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we present a protocol for establishing patient-derived xenograft (PDX) mouse models of chemoresistant triple-negative breast cancer (TNBC). We describe steps for tumor collection, surgical implantation, and serial expansion. We then detail procedures for histopathological validation and in vivo therapeutic assessment to confirm the maintenance of chemoresistance across passages. These models provide a clinically relevant platform to investigate mechanisms of treatment resistance, evaluate novel therapeutic strategies in preclinical settings, and predict therapeutic responses in refractory TNBC.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysAnimalsDisease Models, AnimalDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorFemaleHumansMiceAntineoplastic AgentsBiotechnology and bioengineeringCancerModel Organisms

Identifiers

PMID41774544
PMCPMC12969394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.